Corcept Therapeutics Incorporated
CORT
$73.06
-$3.59-4.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.92% | 25.71% | 30.93% | 39.94% | 39.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.92% | 25.71% | 30.93% | 39.94% | 39.67% |
| Cost of Revenue | 43.91% | 44.28% | 50.75% | 60.17% | 52.88% |
| Gross Profit | 17.53% | 25.45% | 30.65% | 39.67% | 39.49% |
| SG&A Expenses | 64.63% | 63.08% | 63.94% | 52.13% | 36.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.39% | 39.20% | 43.25% | 43.32% | 37.73% |
| Operating Income | -54.42% | -20.62% | -9.44% | 28.12% | 46.63% |
| Income Before Tax | -46.79% | -15.74% | -3.54% | 29.65% | 48.49% |
| Income Tax Expenses | -171.76% | -131.27% | -90.81% | 10.13% | 18.82% |
| Earnings from Continuing Operations | -25.18% | 6.09% | 13.53% | 33.04% | 55.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.18% | 6.09% | 13.53% | 33.04% | 55.19% |
| EBIT | -54.42% | -20.62% | -9.44% | 28.12% | 46.63% |
| EBITDA | -53.86% | -20.11% | -9.30% | 27.62% | 45.17% |
| EPS Basic | -26.14% | 4.46% | 11.77% | 32.10% | 56.08% |
| Normalized Basic EPS | -47.39% | -16.88% | -4.90% | 29.72% | 50.58% |
| EPS Diluted | -30.55% | -0.44% | 8.96% | 29.99% | 55.50% |
| Normalized Diluted EPS | -50.43% | -20.47% | -7.27% | 27.91% | 49.99% |
| Average Basic Shares Outstanding | 0.89% | 1.18% | 1.23% | -0.34% | -1.87% |
| Average Diluted Shares Outstanding | 7.28% | 6.62% | 4.93% | 1.42% | -1.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |